SecBot SecBot
8-K ·Filed Jun 22, 2026

APGE

Apogee Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed4mo ago SEC0001140361-26-025841
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

This licensing deal adds a preclinical IL-31R program to Apogee's pipeline, but no financial results or near-term catalysts are provided. Monitor for future IND filings and Phase I initiation, which would trigger the first $5.25M milestone. The deal structure is standard for early-stage biotech licensing and does not change the near-term outlook.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$132.55
T+0 close · Jun 22, 2026 · via day close
Latest settled
+1.09%
T+20 · $134.00
Vs SPY
+1.24%
α at T+20
Next horizon
T+60
due 2mo ago
  1. T+0 · Jun 22 $132.55entry
  2. T+1 · 5mo ago +0.25%α +1.70% · $132.88
  3. T+5 · 5mo ago +0.05%α +0.50% · $132.61
  4. T+20 · 4mo ago +1.09%α +1.24% · $134.00
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics entered into an exclusive worldwide license agreement with Paragon Therapeutics for antibodies targeting IL-31R, a novel pipeline asset. The deal includes up to $23.25 million in development and regulatory milestones plus low-single-digit royalties on net sales. This expands Apogee's pipeline into a new target for inflammatory diseases but remains at the preclinical stage with no near-term catalysts.

Key Financial Metrics

Deal Value
$23.3M
Deal Type
license

Key Facts

  • Exclusive worldwide license from Paragon for IL-31R-directed antibodies
  • Up to $23.25 million in milestone payments: $5.25M (Phase I), $3M (Phase II), $5M (Phase III), $10M (FDA approval)
  • Low-single-digit royalty on net sales of licensed products
  • Optional CMC activities with fees ranging from $1.3M to $2.0M
  • Paragon retains non-exclusive rights to develop multispecific antibodies targeting IL-31R
  • Apogee is solely responsible for all development, manufacturing, and commercialization costs

Financial Impact

Up to $23.25 million in milestone payments plus low-single-digit royalties; optional CMC fees of $1.3M–$2.0M

milestone paymentsroyaltiesdevelopment costs

Risk Factors

  • Preclinical stage: no guarantee of clinical success or regulatory approval
  • Milestone and royalty obligations create future cash outflows without guaranteed returns
  • Paragon retains rights to multispecific antibodies that could compete with Apogee's monospecific products

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-025841
Document: ef20076542_ex10-1.htm0001140361-26-025841
Document: ef20076542_8k.htm0001140361-26-025841
Document: 0001140361-26-025841-index-headers.html0001140361-26-025841
Document: 0001140361-26-025841-index.html0001140361-26-025841
Document: 0001140361-26-025841.txt0001140361-26-025841

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens in 9h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026